Tirzepatide alone lowered A1c by about 2 points in Chinese adults with early type 2 diabetes

A phase 3 trial in China found that tirzepatide used by itself lowered A1c substantially more than placebo and produced weight loss in adults with early type 2 diabetes, according to the published study results ^[1]. The trial, called SURPASS-CN-MONO, reported no clinically significant or severe low blood sugar in any tirzepatide group ^[1].

The study ran at 29 centers in China and randomized 206 adults with type 2 diabetes who had not taken a blood sugar–lowering medication in the previous 90 days ^[1]. Participants received once-weekly injections of 5 mg (52 people), 10 mg (51) or 15 mg (52) tirzepatide, or placebo (51), in a double-blind design, meaning neither the participants nor the investigators knew who was receiving which treatment ^[1]. The primary measure was the average change in HbA1c — a marker of average blood sugar over roughly three months — from the start of the study to week 40 ^[1].

A1c fell by an average of 2.17 percentage points with 5 mg, 2.06 points with 10 mg and 2.15 points with 15 mg, compared with 0.13 points with placebo ^[1]. The differences versus placebo were 2.04 points (95% confidence interval 2.46 to 1.63), 1.93 points (2.35 to 1.51) and 2.02 points (2.44 to 1.60), all with p values below 0.001 ^[1]. In this trial the three doses produced similar A1c reductions rather than a steady rise with each higher dose ^[1]. The published figures come from the efficacy estimand, the statistical approach the authors used for the primary analysis ^[1].

Average body weight fell by 6.0 kg with 5 mg, 6.1 kg with 10 mg and 9.7 kg with 15 mg, compared with 1.0 kg with placebo; every comparison was significant at p below 0.001 ^[1]. The most common side effects in the tirzepatide groups were gastrointestinal ^[1]. No participant had clinically significant hypoglycemia, defined in the study as a blood sugar below 54 mg/dL, and no severe hypoglycemia occurred ^[1]. The authors said the safety profile matched that of earlier tirzepatide trials ^[1]. Eli Lilly funded the trial, and two of the authors are Lilly employees who hold company stock ^[1]. The abstract carries a 2026 copyright line from Elsevier ^[1].

The trial followed participants for 40 weeks and enrolled 206 people, all in China ^[1]. Whether similar results would appear in US patients or over longer periods has not been reported ^[1]. No regulatory filing, review or approval timeline in China or the United States is described in the published abstract ^[1].

Why it matters for patients

This trial tested tirzepatide as a stand-alone first treatment, in people who had not recently taken another diabetes drug ^[1]. That is a different question from how the drug performs when added to existing therapy, which this study does not address ^[1].

For patients weighing tolerability, the side effect pattern may be the most familiar part of the report: gastrointestinal symptoms were the most common treatment-emergent adverse events, the same pattern seen in earlier tirzepatide trials ^[1]. No low blood sugar episodes of clinical concern appeared when tirzepatide was used by itself ^[1]. The trial does not report results for people taking other diabetes medications alongside tirzepatide ^[1].

The findings come from adults in China, and whether they apply to US patients has not been established by this study ^[1]. The abstract also does not report how well the drug worked in the two dosing groups the study design did not require people to stay in, or how many participants stopped treatment because of side effects; those details are not included in the published summary ^[1].

A1c improvements of about 2 percentage points were measured against a placebo group whose A1c barely moved, which shows how the two groups compared over the same 40 weeks of care ^[1]. Weight loss in the trial ranged from 6.0 kg at the lowest dose to 9.7 kg at the highest dose ^[1].